3CAI - C10H8ClNO - Bertin Bioreagent

Confirm delete?

3CAI

Zoom

Cat No: 14303

Biochemicals - Kinase Inhibitors

3CAI is an inhibitor of Akt1 and Akt2 with anticancer activity.{41924} It inhibits Akt1 and Akt2 in a kinase assay in a concentration-dependent manner, but has no effect on MEK1, JNK1, ERK1, or PDZ binding kinase (PBK) when used at a concentration of ...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

2-chloro-1-(1H-indol-3-yl)-ethanone

Correlated keywords:

3-CAI Akt-1 2 MEK JNK ERK HCT-116 HT29 e-NOS anti-cancer chloroacetylindole

Product Overview:
3CAI is an inhibitor of Akt1 and Akt2 with anticancer activity.{41924} It inhibits Akt1 and Akt2 in a kinase assay in a concentration-dependent manner, but has no effect on MEK1, JNK1, ERK1, or PDZ binding kinase (PBK) when used at a concentration of 1 µM. 3CAI (4 µM) increases apoptosis in HCT116 and HT-29 colon cancer cells and inhibits the growth of HCT116 cells in vitro in a concentration-dependent manner. Oral administration of 3CAI (30 mg/kg) reduces tumor growth in an HCT116 mouse xenograft model. It also decreases status epilepticus-induced vasogenic edema to 0.46-fold of vehicle control levels and reduces increases in endothelial nitric oxide synthase (eNOS) levels in the piriform cortex in rats when administered at a dose of 25 µM.{41925}

Size	250 mg
Shipping	dry ice
CAS Number	28755-03-5
Molecular Formula	C₁₀H₈ClNO
SMILES	O=C(CCl)C1=CNC2=CC=CC=C21
Molecular Weight	193,6
Formulation	A crystalline solid
Purity	≥95%
Custom Code	2905.11
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.